← 홈

Antibody · 림프종

169개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 169개
AntibodyBHotMerckvedotin plus pembrolizumab …Phase 2

PD-1 Blocking Antibody (Pembrolizumab, Pembrolizumab (PD-1 Blocking Antibody))

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type · PD-1

#PD-1#Antibody#Phase2#인기#항체+5
효능 ORR 75%임상시험 151상태 ACTIVE
AntibodyAHotRochePhase 3

Obinutuzumab (Obinutuzumab)

Breast Adenocarcinoma; Metastatic Breast Carcinoma · B-cell Lymphoma

#B-cellLymphoma#Antibody#Phase3#인기#항체+5
효능 ORR 100%임상시험 114상태 RECRUITING
AntibodyBHotRochePhase 3

R (Rituximab, Rituximab (R))

Primary Central Nervous System Lymphoma · B-Cell Lymphoma

#B-CellLymphoma#Antibody#Phase3#인기#항체+4
효능 ORR 95%임상시험 114상태 ACTIVE
AntibodyCMiltenyi Biomedicine GmbHPhase 3

Alemtuzumab (Alemtuzumab)

Leukemia; Lymphoma · Fanconi Anemia

#FanconiAnemia#Antibody#Phase3#인기#항체+5
효능 ORR 33%임상시험 71상태 DISCONTINUED
AntibodyHoffmann-La Rochevedotin plus bendamustine a…Phase 3

Glofitamab (Glofitamab)

Diffuse Large B Cell Lymphoma (DLBCL); High Grade B Cell Lymphoma · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase3#인기#항체+5
임상시험 66상태 RECRUITING
AntibodyNovartisPhase 3

Ofatumumab (Ofatumumab)

Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma · Leukemia

#Leukemia#Antibody#Phase3#인기#항체+5
효능 ORR 78.4%임상시험 65상태 RECRUITING
AntibodyGenentech, Inc.Phase 3

Tiragolumab (Tiragolumab)

Multiple Myeloma; Non-Hodgkin Lymphoma · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase3#인기#항체+5
효능 ORR 77.3%임상시험 64상태 ACTIVE
AntibodyBristol Myers Squibbvedotin in patients with re…Phase 2

nivolumab (Opdivo, Nivolumab and Ipilimumab)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#인기#항체+5
효능 ORR 77.8%임상시험 62상태 RECRUITING
AntibodyBristol Myers Squibbvedotin after avelumabPhase 2

Opdivo (Nivolumab, Nivolumab (Opdivo))

Solid Tumors · Anaplastic Large Cell Lymphoma, ALK-Posi

#AnaplasticLargeCellLymphomaALK-P#Antibody#Phase2#인기#항체+5
효능 ORR 100%임상시험 61상태 RECRUITING
AntibodyNovartisApproved

Basiliximab (Basiliximab)

Type 1 Diabetes Mellitus · Extranodal NK/T-cell Lymphoma

#ExtranodalNKT-cellLymphoma#Antibody#Approved#인기#항체+4
효능 ORR 10%임상시험 58상태 ACTIVE
AntibodySeagenvedotin-containing regimen …Phase 2

Brentuximab (Brentuximab)

Diffuse Large B Cell Lymphoma; Mediastinal Large B-cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#Antibody#Phase2#인기#항체+5
효능 ORR 89.5%임상시험 51상태 DISCONTINUED
AntibodyGenmabPhase 2

Epcoritamab (Epcoritamab)

Diffuse Large B-Cell Lymphoma; Follicular Lymphoma · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#Antibody#Phase2#인기#항체+5
효능 ORR 0%임상시험 50상태 RECRUITING
AntibodyMridula George, MDderuxtecan, datopotamab der…Phase 2

Retifanlimab (Retifanlimab)

Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Breast Carcinoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase2#항체#면역항체+5
효능 ORR 100%임상시험 49상태 RECRUITING
AntibodyEpizyme, Inc.vedotin, rituximab, cycloph…Phase 2

Tafasitamab (Tafasitamab)

Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase2#항체#면역항체+5
효능 ORR 90.9%임상시험 48상태 DISCONTINUED
AntibodyBristol Myers SquibbPhase 2

nivolumab (Opdivo, Nivolumab plus Ipilimumab)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#항체#면역항체+5
효능 ORR 77.8%임상시험 32상태 RECRUITING
AntibodyRochevedotin-containing regimens…Phase 2

Rituximab and Bendamustine (Rituximab and Bendamustine)

Diffuse Large B-Cell Lymphoma; Follicular Lymphoma · MALT LYMPHOMA

#MALTLYMPHOMA#Antibody#Phase2#항체#면역항체+5
효능 ORR 90%임상시험 32상태 RECRUITING
AntibodyRochevedotin plus rituximab and …Phase 2

Rituximab and Lenalidomide (Rituximab and Lenalidomide)

Diffuse Large B-Cell Lymphoma; Follicular Lymphoma · Lymphoma of the Mucosa Associated Lympho

#LymphomaoftheMucosaAssociatedLym#Antibody#Phase2#항체#면역항체+5
효능 ORR 100%임상시험 32상태 RECRUITING
AntibodyRochederuxtecan, are effective i…Phase 2

trastuzumab (Herceptin, Trastuzumab plus Pertuzumab)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#항체#면역항체+5
효능 ORR 79.5%임상시험 32상태 RECRUITING
AntibodyRocheVedotin-Based Polatuzumab V…Phase 2

rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone)

Diffuse Large B-Cell Lymphoma; Follicular Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+5
효능 ORR 76%임상시험 32상태 RECRUITING
AntibodystaleRochePreclinical

Mabthera®, Roche Pty Ltd, Basel, Switzerland (Rituximab, Rituximab (Mabthera®, Roche Pty Ltd, Basel, Switzerland))

Non Hodgkin Lymphoma · Non Hodgkin Lymphoma

#NonHodgkinLymphoma#Antibody#Preclinical#항체#면역항체+2
효능 ORR 4%임상시험 31상태 ACTIVE

1 / 9 페이지

← 이전다음 →